← All trials
NCT02754999
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- May 17, 2017
- Completion date
- May 17, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 103
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Prolong PharmaceuticalsLead sponsor
- Prolong PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.